One of the most important goals for any company is transparent and trustworthy corporate governance. Compliance with laws, guidelines, regulations, ordinances, as well as the internal rules and regulations provides the basis for successful entrepreneurial activity, and constitute a component of good corporate governance.
APONTIS PHARMA's business model is designed for the long term and all measures are geared towards the goal of sustainable positive development. The Executive Board and Supervisory Board identify with the aim of the German Corporate Governance Code to promote good corporate governance oriented towards the benefit of shareholders, employees and customers.
We are committed to building and maintaining a trust-based relationship with our key stakeholders. We provide our shareholders and financial markets with timely, accurate and complete financial information. At APONTIS PHARMA, we continuously work to increase our resilience, because the ability to continue business processes without disruption is critical to our patients, customers and employees. Thus, as a reliable partner to our stakeholders, we strive to ensure long-term value creation in the market.
Contents on this page
Corporate Governance
Good corporate governance determines our actions.
4. Interim announcement – APONTIS PHARMA AG Share buyback
4. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR)
3. Interim announcement – APONTIS PHARMA AG Share buyback
3. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR)
2. Interim announcement – APONTIS PHARMA AG Share buyback
2. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR)
1. Interim announcement – APONTIS PHARMA AG Share buyback
1. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR)
APONTIS PHARMA AG
APONTIS PHARMA AG: Notice according to Article 2 paragraph 1 of Delegated Regulation (EU) 2016/1052
Share buyback program 2022/II
15. Interim announcement – APONTIS PHARMA AG Share buyback
15. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR) in connection with Article 2 paragraph 2 and paragraph 3 of the Delegated Regulation (EU) No. 2016/1052
14. Interim announcement – APONTIS PHARMA AG Share buyback
14. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR) in connection with Article 2 paragraph 2 and paragraph 3 of the Delegated Regulation (EU) No. 2016/1052
13. Interim announcement – APONTIS PHARMA AG Share buyback
13. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR) in connection with Article 2 paragraph 2 and paragraph 3 of the Delegated Regulation (EU) No. 2016/1052
12. Interim announcement – APONTIS PHARMA AG Share buyback
12. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR) in connection with Article 2 paragraph 2 and paragraph 3 of the Delegated Regulation (EU) No. 2016/1052
11. Interim announcement – APONTIS PHARMA AG Share buyback
11. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR) in connection with Article 2 paragraph 2 and paragraph 3 of the Delegated Regulation (EU) No. 2016/1052
10. Interim announcement – APONTIS PHARMA AG Share buyback
10. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR) in connection with Article 2 paragraph 2 and paragraph 3 of the Delegated Regulation (EU) No. 2016/1052
9. Interim announcement – APONTIS PHARMA AG Share buyback
9. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR) in connection with Article 2 paragraph 2 and paragraph 3 of the Delegated Regulation (EU) No. 2016/1052
8. Interim announcement – APONTIS PHARMA AG Share buyback
8. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR) in connection with Article 2 paragraph 2 and paragraph 3 of the Delegated Regulation (EU) No. 2016/1052
7. Interim announcement – APONTIS PHARMA AG Share buyback
7. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR) in connection with Article 2 paragraph 2 and paragraph 3 of the Delegated Regulation (EU) No. 2016/1052
6. Interim announcement – APONTIS PHARMA AG Share buyback
6. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR) in connection with Article 2 paragraph 2 and paragraph 3 of the Delegated Regulation (EU) No. 2016/1052
5. Interim announcement – APONTIS PHARMA AG Share buyback
5. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR) in connection with Article 2 paragraph 2 and paragraph 3 of the Delegated Regulation (EU) No. 2016/1052
4. Interim announcement – APONTIS PHARMA AG Share buyback
4. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR) in connection with Article 2 paragraph 2 and paragraph 3 of the Delegated Regulation (EU) No. 2016/1052
3. Interim announcement – APONTIS PHARMA AG Share buyback
3. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR) in connection with Article 2 paragraph 2 and paragraph 3 of the Delegated Regulation (EU) No. 2016/1052
2. Interim announcement – APONTIS PHARMA AG Share buyback
2. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR) in connection with Article 2 paragraph 2 and paragraph 3 of the Delegated Regulation (EU) No. 2016/1052
1. Interim announcement – APONTIS PHARMA AG Share buyback
1. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR) in connection with Article 2 paragraph 2 and paragraph 3 of the Delegated Regulation (EU) No. 2016/1052
Whistleblower System
APONTIS PHARMA AG has set up a whistleblower system in connection with its Code of Conduct, which is available not only to employees of the company but also to external parties. It allows you to inform us about violations of legal regulations or compliance rules and thus contribute to their detection. For example, you can inform us about cases of fraud, bribery, antitrust violations, or violations of money laundering laws. If you have concrete, substantiated indications of legal violations or breaches of rules within the APONTIS PHARMA Group, you can contact APONTIS PHARMA AG via our external ombudsman.
As external ombudsman, APONTIS PHARMA AG has appointed Stephan Rheinwald, attorney-at-law. Mr. Rheinwald accepts information from all employees of the APONTIS PHARMA Group and third parties, such as business partners or customers, about suspected criminal offenses and other violations of laws and regulations related to the APONTIS PHARMA Group. No costs or attorney's fees are incurred by the whistleblowers for this service. At the request of whistleblowers, the ombudsman protects their identity in the best possible way. All incoming information is treated confidentially and examined by specially trained persons at Compliance Officer Services GmbH.
Stephan Rheinwald
Compliance Officer Services
GmbH Willy-Brandt-Allee 18
53113 Bonn Germany
Phone: +49 228 35036-290
Fax: +49 228 35036-292
Email: s.rheinwald@cos-legal.eu
www.cos-gmbh.eu
As external ombudsman, APONTIS PHARMA AG has appointed Stephan Rheinwald, attorney-at-law. Mr. Rheinwald accepts information from all employees of the APONTIS PHARMA Group and third parties, such as business partners or customers, about suspected criminal offenses and other violations of laws and regulations related to the APONTIS PHARMA Group. No costs or attorney's fees are incurred by the whistleblowers for this service. At the request of whistleblowers, the ombudsman protects their identity in the best possible way. All incoming information is treated confidentially and examined by specially trained persons at Compliance Officer Services GmbH.
Stephan Rheinwald
Compliance Officer Services
GmbH Willy-Brandt-Allee 18
53113 Bonn Germany
Phone: +49 228 35036-290
Fax: +49 228 35036-292
Email: s.rheinwald@cos-legal.eu
www.cos-gmbh.eu
